All Stories

  1. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

    Article • Mediators of Inflammation, June 2019, Hindawi Publishing Corporation

    Dr Cristina M Ramo-Tello

  2. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

    Article • Trials, May 2019, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  3. Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

    Article • CNS Neuroscience & Therapeutics, May 2019, Wiley

    Dr Cristina M Ramo-Tello

  4. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Article • Multiple Sclerosis and Related Disorders, February 2019, Elsevier

    Dr Cristina M Ramo-Tello

  5. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, January 2019, BMJ

    Dr Cristina M Ramo-Tello

  6. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial

    Article • European Journal of Neurology, November 2018, Wiley

    Dr Cristina M Ramo-Tello

  7. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

    Article • European Journal of Neurology, November 2018, Wiley

    Dr Cristina M Ramo-Tello

  8. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

    Article • JAMA Neurology, November 2018, American Medical Association (AMA)

    Dr Cristina M Ramo-Tello

  9. Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin

    Article • Scientific Reports, October 2018, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  10. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    Article • CNS Neuroscience & Therapeutics, April 2018, Wiley

    QUIRANT BIBIANA, Dr Cristina M Ramo-Tello

  11. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    Article • Multiple Sclerosis Journal, October 2017, SAGE Publications

    Dr Cristina M Ramo-Tello

  12. Hepatitis tóxica tras tratamiento concomitante con interferón beta y aloe vera en un paciente con esclerosis múltiple: a propósito de un caso

    Article • Neurología, October 2017, Elsevier

    Dr Cristina M Ramo-Tello

  13. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Article • Neurology, August 2017, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  14. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

    Article • Brain, August 2017, Oxford University Press (OUP)

    Dr Cristina M Ramo-Tello

  15. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients

    Article • Cytometry Part B Clinical Cytometry, April 2017, Wiley

    Dr Cristina M Ramo-Tello

  16. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

    Article • New England Journal of Medicine, January 2017, New England Journal of Medicine (NEJM/MMS)

    Dr Cristina M Ramo-Tello

  17. Defining secondary progressive multiple sclerosis

    Article • Brain, July 2016, Oxford University Press (OUP)

    Dr Tomas Kalincik, Dr Cristina M Ramo-Tello

  18. Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients

    Article • Journal of Neuroinflammation, May 2016, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  19. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients

    Article • CNS Neuroscience & Therapeutics, April 2016, Wiley

    Dr Cristina M Ramo-Tello

  20. Neuromyelitis optica spectrum disorders

    Article • Neurology Neuroimmunology & Neuroinflammation, April 2016, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  21. Mielitis. Diferencias entre esclerosis múltiple y otras etiologías

    Article • Neurología, March 2016, Elsevier

    Dr Cristina M Ramo-Tello

  22. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients

    Article • Autoimmunity, February 2016, Taylor & Francis

    Dr Cristina M Ramo-Tello

  23. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen

    Article • Neurodegenerative Disease Management, October 2015, Future Medicine

    Dr Cristina M Ramo-Tello

  24. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Article • Multiple Sclerosis Journal, June 2015, SAGE Publications

    Dr Cristina M Ramo-Tello

  25. Beneficial Effect of Tolerogenic Dendritic Cells Pulsed with MOG Autoantigen in Experimental Autoimmune Encephalomyelitis

    Article • CNS Neuroscience & Therapeutics, November 2014, Wiley

    Dr Cristina M Ramo-Tello

  26. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses

    Article • Multiple Sclerosis Journal, August 2014, SAGE Publications

    Dr Cristina M Ramo-Tello

  27. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

    Article • Multiple Sclerosis Journal, October 2013, SAGE Publications

    Dr Cristina M Ramo-Tello

  28. Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients

    Article • BMC Neurology, September 2012, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  29. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients

    Article • European Journal of Immunology, March 2012, Wiley

    Dr Cristina M Ramo-Tello

  30. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice

    Article • Journal of Immunological Methods, August 2011, Elsevier

    Dr Cristina M Ramo-Tello

  31. Análisis del dolor en pacientes con esclerosis múltiple

    Article • Neurología, May 2011, Elsevier

    Dr Cristina M Ramo-Tello

  32. Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

    Article • European Neurology, January 2011, Karger Publishers

    Dr Cristina M Ramo-Tello

  33. Comparative study of clinical grade human tolerogenic dendritic cells

    Article • Journal of Translational Medicine, January 2011, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  34. Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis

    Article • European Journal of Neurology, December 2010, Wiley

    Dr Cristina M Ramo-Tello

  35. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

    Article • European Journal of Neurology, December 2010, Wiley

    Dr Cristina M Ramo-Tello

  36. Transverse Myelitis Affecting More Than 4 Spinal Segments Associated with Systemic Lupus Erythematosus: Clinical, Immunological, and Radiological Characteristics of 22 Patients

    Article • Seminars in Arthritis and Rheumatism, February 2010, Elsevier

    Dr Cristina M Ramo-Tello

  37. Myelin peptides in multiple sclerosis

    Article • Autoimmunity Reviews, July 2009, Elsevier

    Dr Cristina M Ramo-Tello

  38. Evaluation of the Anti-HIV Activity of Natalizumab—An Antibody Against Integrin alpha4

    Article • Antiviral Research, May 2009, Elsevier

    Dr Cristina M Ramo-Tello

  39. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

    Article • AIDS, January 2009, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  40. S.41. Specific T Cell Proliferative Response in Patients with Relapsing-remitting Multiple Sclerosis to a Definite Group of Myelin Peptides

    Article • Clinical Immunology, January 2009, Elsevier

    Dr Cristina M Ramo-Tello